Majority (n = 186, 76.5%) of them were included in AML-MRC by WHO2016 while a considerable proportion were previously classified as ‘AML with RUNX1 mutation’ (n = 20, 8.2%) or AML-NOS (n = 37, 15.2%) by the same system. This evidence concerns the gene RUNX1 and acute myeloid leukemia.